My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Traws Pharma, Inc. - Common Stock (NQ:TRAW)

2.250 +0.430 (+23.63%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Traws Pharma, Inc. - Common Stock

< Previous 1 2 3 Next >
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Appoints Mark Guerin as Chief Financial Officer
Via Investor Brand Network
Annovis Appoints Mark Guerin as Chief Financial Officer
From Annovis Bio Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For August 14, 2025
 
Via Benzinga
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
From Traws Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Traws Pharma Posts Q2 Revenue Jump
Via The Motley Fool
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
From Traws Pharma, Inc.
Via GlobeNewswire
Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma
The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates. 
Via Stocktwits
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
From Traws Pharma, Inc.
Via GlobeNewswire
Why RH Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard Surge – More Stocks Inside!
Via AB Newswire
What's going on in today's session
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Which stocks are moving on Tuesday?
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Dow Gains Over 100 Points; US Job Openings Increase In April
 
Via Benzinga
Topics Stocks
Tuesday's session: gap up and gap down stocks
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
US Stocks Mixed; Dollar General Posts Upbeat Earnings
 
Via Benzinga
Tuesday's pre-market session: top gainers and losers
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Reports First Quarter 2025 Results and Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Reports Full Year 2024 Results and Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Announces Management Updates
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates
From Traws Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.